Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide (NAP, AL-108) in Predicted Tauopathies A 12 Week Randomized, Double Blind, Placebo-Controlled Pilot Study of Davunetide(NAP, AL-108) in Pre ...
Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17;Corticobasal Degeneration Syndrome;Progressive Nonfluent Aphasia Predicted Tauopathies, Including;Progressive Supranuclear Palsy;Frontotemporal Dementia With Parkins ...